AAAAAA

   
Results: 1-13 |
Results: 13
Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants
Authors: Dykes, C Fox, K Lloyd, A Chiulli, M Morse, E Demeter, LM
Citation: C. Dykes et al., Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants, VIROLOGY, 285(2), 2001, pp. 193-203
Mutation of the methylated tRNA(3)(Lys) residue A58 disrupts reverse transcription and inhibits replication of human immunodeficiency virus type 1
Authors: Renda, MJ Rosenblatt, JD Klimatcheva, E Demeter, LM Bambara, RA Planelles, V
Citation: Mj. Renda et al., Mutation of the methylated tRNA(3)(Lys) residue A58 disrupts reverse transcription and inhibits replication of human immunodeficiency virus type 1, J VIROLOGY, 75(20), 2001, pp. 9671-9678
Use of tissue culture-amplified human immunodeficiency virus type 1 to study evolutionary changes in vivo - Reply
Authors: Dykes, C Demeter, LM
Citation: C. Dykes et Lm. Demeter, Use of tissue culture-amplified human immunodeficiency virus type 1 to study evolutionary changes in vivo - Reply, J INFEC DIS, 183(1), 2001, pp. 174-175
The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleosidereverse transcriptase inhibitors alters the size distribution of RNase H cleavages
Authors: Archer, RH Wisniewski, M Bambara, RA Demeter, LM
Citation: Rh. Archer et al., The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleosidereverse transcriptase inhibitors alters the size distribution of RNase H cleavages, BIOCHEM, 40(13), 2001, pp. 4087-4095
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine - AIDS clinical trials group protocol 320
Authors: Demeter, LM Hughes, MD Coombs, RW Jackson, JB Grimes, JM Bosch, RJ Fiscus, SA Spector, SA Squires, KE Fischl, MA Hammer, SM
Citation: Lm. Demeter et al., Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine - AIDS clinical trials group protocol 320, ANN INT MED, 135(11), 2001, pp. 954-964
Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies
Authors: Morse, GD Reichman, RC Fischl, MA Para, M Leedom, J Powderly, W Demeter, LM Resnick, L Bassiakos, Y Timpone, J Cox, S Batts, D
Citation: Gd. Morse et al., Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies, ANTIVIR RES, 45(1), 2000, pp. 47-58
Antiretroviral drug resistance testing in adult HIV-1 infection - Recommendations of an International AIDS Society-USA panel
Authors: Hirsch, MS Brun-Vezinet, F D'Aquila, RT Hammer, SM Johnson, VA Kuritzkes, DR Loveday, C Mellors, JW Clotet, B Conway, B Demeter, LM Vella, S Jacobsen, DM Richman, DD
Citation: Ms. Hirsch et al., Antiretroviral drug resistance testing in adult HIV-1 infection - Recommendations of an International AIDS Society-USA panel, J AM MED A, 283(18), 2000, pp. 2417-2426
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
Authors: Demeter, LM Shafer, RW Meehan, PM Holden-Wiltse, J Fischl, MA Freimuth, WW Para, MF Reichman, RC
Citation: Lm. Demeter et al., Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260), ANTIM AG CH, 44(3), 2000, pp. 794-797
Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture
Authors: Archer, RH Dykes, C Gerondelis, P Lloyd, A Fay, P Reichman, RC Bambara, RA Demeter, LM
Citation: Rh. Archer et al., Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture, J VIROLOGY, 74(18), 2000, pp. 8390-8401
Analysis of env sequence evolution in human immunodeficiency virus-infected patients receiving therapy with nonnucleoside reverse-transcriptase inhibitors
Authors: Dykes, C Meotsikapun, P Dexter, A Berrios, L Chiulli, M Reichman, RC Demeter, LM
Citation: C. Dykes et al., Analysis of env sequence evolution in human immunodeficiency virus-infected patients receiving therapy with nonnucleoside reverse-transcriptase inhibitors, J INFEC DIS, 182(1), 2000, pp. 316-320
ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy
Authors: Para, MF Meehan, P Holden-Wiltse, J Fischl, M Morse, G Shafer, R Demeter, LM Wood, K Nevin, T Virani-Ketter, N Freimuth, WW
Citation: Mf. Para et al., ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy, ANTIM AG CH, 43(6), 1999, pp. 1373-1378
The P236L delavirdine-resistant human immunodeficiency virus type 1 mutantis replication defective and demonstrates alterations in both RNA 5 '-end-and DNA 3 '-end-directed RNase H activities
Authors: Gerondelis, P Archer, RH Palaniappan, C Reichman, RC Fay, PJ Bambara, RA Demeter, LM
Citation: P. Gerondelis et al., The P236L delavirdine-resistant human immunodeficiency virus type 1 mutantis replication defective and demonstrates alterations in both RNA 5 '-end-and DNA 3 '-end-directed RNase H activities, J VIROLOGY, 73(7), 1999, pp. 5803-5813
Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection
Authors: Luque, AE Demeter, LM Reichman, RC
Citation: Ae. Luque et al., Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection, J INFEC DIS, 179(6), 1999, pp. 1405-1409
Risultati: 1-13 |